Literature DB >> 23810504

A multiplexed fragment analysis-based assay for detection of JAK2 exon 12 mutations.

Larissa V Furtado1, Helmut C Weigelin, Kojo S J Elenitoba-Johnson, Bryan L Betz.   

Abstract

Mutations within exon 12 of the JAK2 gene occur in most cases of JAK2 V617F-mutation negative polycythemia vera. Several methods have been developed to identify exon 12 mutations, with both Sanger sequencing and high resolution melting (HRM) being widely used. However, mutations can occur at allelic levels lower than 15%, which may hamper detection by these methods. We developed a novel fragment analysis-based assay capable of detecting nearly all JAK2 exon 12 mutations associated with polycythemia vera down to a sensitivity of 2% mutant allele. Test results were reviewed from a set of 20 reference cases and 1731 consecutive specimens that were referred to our laboratory for testing. Assay performance was compared to sequencing and HRM across a series of 27 specimens with JAK2 exon 12 mutations. Positive cases consisted of 22 with deletion mutations, four with duplications, and one with K539L. Nine cases had mutation levels between 6% and 15% that may not be reliably detected by sequencing or HRM. All cases were easily interpreted in the fragment analysis assay. Sequencing, HRM, and fragment analysis each represent viable platforms for detection of JAK2 exon 12 mutations. Our method performed favorably by providing a simple, robust, and highly sensitive solution for JAK2 exon 12 mutation testing.
Copyright © 2013 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23810504     DOI: 10.1016/j.jmoldx.2013.04.006

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  3 in total

1.  Rapid identification of apolipoprotein E genotypes by high-resolution melting analysis in Chinese Han and African Fang populations.

Authors:  Xiu-Hui Zhan; Guang-Cai Zha; Ji-Wei Jiao; Li-Ye Yang; Xiao-Fen Zhan; Jiang-Tao Chen; Dong-DE Xie; Urbano Monsuy Eyi; Rocio Apicante Matesa; Maximo Miko Ondo Obono; Carlos Sala Ehapo; Er-Jia Wei; Yu-Zhong Zheng; Hui Yang; Min Lin
Journal:  Exp Ther Med       Date:  2014-12-01       Impact factor: 2.447

2.  [Detection of UGT1A1*28 Polymorphism Using Fragment Analysis].

Authors:  Ying Huang; Jian Su; Xiaosui Huang; Danxia Lu; Zhi Xie; Suqing Yang; Weibang Guo; Zhiyi Lv; Hongsui Wu; Xuchao Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-12-20

3.  Genetic-pathologic characterization of myeloproliferative neoplasms.

Authors:  Yonggoo Kim; Joonhong Park; Irene Jo; Gun Dong Lee; Jiyeon Kim; Ahlm Kwon; Hayoung Choi; Woori Jang; Hyojin Chae; Kyungja Han; Ki-Seong Eom; Byung-Sik Cho; Sung-Eun Lee; Jinyoung Yang; Seung-Hwan Shin; Hyunjung Kim; Yoon Ho Ko; Haeil Park; Jong Youl Jin; Seungok Lee; Dong Wook Jekarl; Seung-Ah Yahng; Myungshin Kim
Journal:  Exp Mol Med       Date:  2016-07-22       Impact factor: 8.718

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.